The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Cytokines in Cancer Immunotherapy
Open accessAbstract
Cytokines are molecular messengers that allow the cells of the immune system to communicate with one another to generate a coordinated, robust, but self-limited response to a target antigen. The growing interest over the past two decades in harnessing the immune system to eradicate cancer has been accompanied by heightened efforts to characterize cytokines and exploit their vast signaling networks to develop cancer treatments. The goal of this paper is to review the major cytokines involved in cancer immunotherapy and discuss their basic biology and clinical applications. The paper will also describe new cytokines in pre-clinical development, combinations of biological agents, novel delivery mechanisms, and potential directions for future investigation using cytokines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Cellular and Molecular Immunology
Abbas, A. K., Lichtman, A. H., & Pillai, S. S. (1994) · Cited by 3,583
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Cloning of a new cytokine that induces IFN-γ production by T cells
Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995) · Nature · doi:10.1038/378088a0 · Cited by 2,600
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Trinchieri, G. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.001343 · Cited by 2,399
Cited by
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020) · Current Oncology · doi:10.3747/co.27.5223 · Cited by 954
ESMO Symposium on Immuno-Oncology 2015 Officers and Organisation
(2015) · Annals of Oncology · doi:10.1093/annonc/ · Cited by 733
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Cytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
“In light of the ability of the immune system to recognize and destroy cancer cells, cytokines have been explored in the treatment of cancer (Goldstein and Laszlo 1988; Dranoff 2004; Lee and Margolin 2011; Nicholas and Lesinski 2011; Ardolino et al. 2015).”
BackgroundAugmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 506
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
The immunology of renal cell carcinoma
Díaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 442
Oncolytic viruses for cancer immunotherapy
Hemminki, O., dos Santos, J. M., & Hemminki, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00922-1 · Cited by 351
Cytokine-mediated communication: a quantitative appraisal of immune complexity
Altan-Bonnet, G., & Mukherjee, R. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0131-x · Cited by 341
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 328
The Role of Curcumin in Cancer Treatment
Zoi, V., Galani, V., Lianos, G. D., Voulgaris, S., Kyritsis, A. P., & Alexiou, G. A. (2021) · Biomedicines · doi:10.3390/biomedicines9091086 · Cited by 315
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Souza-Fonseca-Guimaraes, F., Cursons, J., & Huntington, N. D. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.003 · Cited by 279
Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy
Mirlekar, B. (2022) · SAGE Open Medicine · doi:10.1177/20503121211069012 · Cited by 258
Development and validation of an immune gene-set based Prognostic signature in ovarian cancer
Shen, S., Wang, G., Zhang, R., Zhao, Y., Yu, H., Wei, Y., & Chen, F. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.054 · Cited by 257
Macroscale biomaterials strategies for local immunomodulation
Dellacherie, M. O., Seo, B. R., & Mooney, D. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0106-3 · Cited by 255
mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Y., Kowalski, P. S., Huang, Y., Gonzalez, J. T., Heartlein, M. W., DeRosa, F., Delcassian, D., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.012 · Cited by 218
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
Interferons Transcriptionally Up-Regulate MLKL Expression in Cancer Cells
Knuth, A.-K., Rösler, S., Schenk, B., Kowald, L., van Wijk, S. J. L., & Fulda, S. (2019) · Neoplasia · doi:10.1016/j.neo.2018.11.002 · Cited by 63
Epithelial-Macrophage Crosstalk Initiates Sterile Inflammation in Embryonic Skin
Bhattacharjee, O., Ayyangar, U., Kurbet, A. S., Lakshmanan, V., Palakodeti, D., Ginhoux, F., & Raghavan, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718005 · Cited by 14
Metadata
- Authors
- Lee, S., & Margolin, K.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2011-10-13
- Volume
- 3
- Issue
- 4
- Pages
- 3856-3893
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W1997383546
- Cited by
- 693
- References
- 187
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.